

# NUCLEAR MEDICINE


Report & Directory

EDITION 2022

- Marketed Radiopharmaceuticals
- Clinical Radiopharmaceuticals
- Early-Stage Radiopharmaceuticals

# Nuclear Medicine, Edition 2022

- The global market for nuclear medicine reached over US\$ 6 billion in 2021, growing by >10% from 2020
- The market is expected to reach US\$ 35 billion in 2031




# Nuclear Medicine, Edition 2022

---

- Nuclear medicine remains a niche market representing less than 1% of the global pharmaceutical industry, but new opportunities lie ahead, especially in radiotherapeutics
- Radiotherapeutics represented 20% of the global nuclear medicine market in 2021 and are expected to reach ~70% by 2031
- New radiotheranostics under development might lead to much stronger market figures than expected in coming years


# Nuclear Medicine, Edition 2022

- Several new radiotherapeutics with strong revenues' potential to reach the market before 2027




# Nuclear Medicine, Edition 2022

- In 2021, four companies controlled almost 50% of the world nuclear medicine market, the remaining 50% of the market is shared by 87 companies and public institutions.




# Nuclear Medicine, Edition 2022

- Nearly 50 radiopharmaceutical companies were able to raise a total of over US\$ 2.1 billion in 2021 to finance their development. Funding flows increased by almost 50% in 2021 versus 2020. Resources came from institutional investors but also from a growing number of conventional pharmaceutical companies interested in developing radiopharmaceuticals.
- North American firms took 68% of the funding in 2021.




# Nuclear Medicine, Edition 2022

- Several hundreds radiopharmaceuticals are under development, the majority (~80%) of them are targeting Oncology.



# Nuclear Medicine, Edition 2022

- Among the new tracers under development about 40% are labeled with  $^{18}\text{F}$  or  $^{68}\text{Ga}$  – and drugs are in priority labeled with  $^{177}\text{Lu}$  or  $^{225}\text{Ac}$  (15%).






# Nuclear Medicine, Edition 2022

---

- During 2021, over 100 radiopharmaceuticals were marketed around the World, but some were only available locally
- The top 5 radiopharmaceuticals accounted for ~20% of the world market
- $^{99m}\text{Tc}$  based radiopharmaceuticals accounted for less than 50% of the world market (in US\$), radiotherapeutics accounted for 20%
- Innovative solutions and additional sources will also emerge to cover the need for  $^{99}\text{Mo}$
- The concept of radiotheranostics is now in all minds.  $^{177}\text{Lu}$  labeled drugs will mainly develop in parallel to their equivalent  $^{68}\text{Ga}$  or  $^{89}\text{Zr}$  labeled tracers (radiotheranostic approach).

# Nuclear Medicine, Edition 2022

- Over 150 companies are currently developing one or more radiodiagnostic or radiotherapeutic from their own pipeline



# Nuclear Medicine, Edition 2022

---

- Nuclear Medicine Report & Directory Edition 2022
  - A set of three reports (~3,500 pages)
  - 970 products extensively described including radiopharmaceuticals under clinical or preclinical/early stage development and including more than 120 radionuclides and generators
  - 380 companies active in NM comprehensively profiled
  - 3,100 bibliographical references and their Web links
- Opportunities exist not only in diagnostic radiopharmaceuticals, but the radiotherapeutic development pipelines show a quite high number of products that could be marketed before the end of 2027.
- Numerous opportunities exist for larger groups or investors to finance such development, and/or to merge with some partners.
- These three documents aim to support the reader in the development of their strategies in this industry.

# How to subscribe?

---

To obtain more details and sample pages for one of our reports and directories, please send an email to Paul-Emmanuel Goethals at [peg@medraysintell.com](mailto:peg@medraysintell.com)



# Authors

---

**Paul-Emmanuel GOETHALS**, MBA



Louvain-la-Neuve, Belgium  
[peg@medraysintell.com](mailto:peg@medraysintell.com)  
Phone: +32 491 080 968

**Richard ZIMMERMANN**, PhD



Lalaye, France  
[rz@medraysintell.com](mailto:rz@medraysintell.com)  
Phone: +33 6 82 80 06 00



**Visit us at**

**[www.medraysintell.com](http://www.medraysintell.com)**

# About MEDraysintell




Experts with a combined century of experience in

- Nuclear Medicine
- Cyclotrons
- Particle therapy
- Brachytherapy

MEDraysintell provides strategic intelligence for the radiation healthcare to help clients understand

- Markets and Competitive environment
- Potential for M&A
- Technology development

The most comprehensive set of reports & directories with over 4,600 pages of unrivaled intelligence, covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment



# Disclaimer

---

This MEDraysintell presentation and information contained herein, coming from the report “Nuclear Medicine World Report & Directory, Edition 2022” is believed to be accurate at the time of publication; it has been gathered in good faith from several public sources, but the authors are not in a position to guarantee its accuracy. The authors do not accept any responsibility for the content of this report/presentation. Information contained herein may be of a speculative nature and must be used with careful consideration. The authors assume no liability for any loss or damage – including but not limited to lost time, lost money, lost profits, lost customers – that may result from any use of the information or actions taken based on any analyses, projections, discussions, recommendations, or conclusions of any kind presented in this report/presentation.